- Home
- ARWR
as 05-09-2025 4:00pm EST
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Upcoming Earnings Alert:
Get ready for potential market movements as Arrowhead Pharmaceuticals Inc. ARWR prepares to release earnings report on 12 May 2025.
| Founded: | 2003 | Country: | United States |
| Employees: | N/A | City: | PASADENA |
| Market Cap: | 1.8B | IPO Year: | 1993 |
| Target Price: | $41.44 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.57 - $30.41 | Next Earning Date: | 05-12-2025 |
| Revenue: | $2,500,000 | Revenue Growth: | -98.62% |
| Revenue Growth (this year): | 4380.43% | Revenue Growth (next year): | 64.24% |
Stock Insider Trading Activity of Arrowhead Pharmaceuticals Inc. (ARWR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Mar 13 '25 | Sell | $15.07 | 51,425 | $774,974.75 | 4,062,377 | |
| Anzalone Christopher Richard | ARWR | Chief Executive Officer | Mar 3 '25 | Sell | $17.53 | 300,000 | $5,274,333.67 | 4,062,377 |
Latest Arrowhead Pharmaceuticals Inc. News
ARWR Breaking Stock News: Dive into ARWR Ticker-Specific Updates for Smart Investing
Zacks
3 days ago
SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
Business Wire
3 days ago
Arrowhead Pharmaceuticals to Participate in May 2025 Investor Conferences
Argus Research
3 days ago
ARWR: What does Argus have to say about ARWR?
Insider Monkey
5 days ago
Why Arrowhead Pharmaceuticals, Inc. (ARWR) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential
Business Wire
9 days ago
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Second Quarter Results
Argus Research
17 days ago
ARWR: Lowering target price to $13.00
Argus Research
24 days ago
ARWR: Raising target price to $14.00
MT Newswires
24 days ago
Arrowhead Pharmaceuticals Names Daniel Apel Chief Financial Officer
Compare ARWR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ARWR Arrowhead Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.